These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1251 related items for PubMed ID: 21889780

  • 1. [OMICS and biomarkers of glial tumors].
    Idbaih A.
    Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M.
    Clin Cancer Res; 2005 Feb 01; 11(3):1119-28. PubMed ID: 15709179
    [Abstract] [Full Text] [Related]

  • 4. [Histological and molecular classification of gliomas].
    Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C.
    Rev Neurol (Paris); 2008 Feb 01; 164(6-7):505-15. PubMed ID: 18565348
    [Abstract] [Full Text] [Related]

  • 5. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A.
    Acta Neuropathol; 2008 Dec 01; 116(6):597-602. PubMed ID: 18985363
    [Abstract] [Full Text] [Related]

  • 6. Molecular pathways in the formation of gliomas.
    von Deimling A, Louis DN, Wiestler OD.
    Glia; 1995 Nov 01; 15(3):328-38. PubMed ID: 8586467
    [Abstract] [Full Text] [Related]

  • 7. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
    Figarella-Branger D, Maues de Paula A, Colin C, Bouvier C.
    Rev Neurol (Paris); 2011 Oct 01; 167(10):683-90. PubMed ID: 21889777
    [Abstract] [Full Text] [Related]

  • 8. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A.
    Acta Neuropathol; 2010 Dec 01; 120(6):707-18. PubMed ID: 21088844
    [Abstract] [Full Text] [Related]

  • 9. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A.
    Acta Neuropathol; 2009 Oct 01; 118(4):469-74. PubMed ID: 19554337
    [Abstract] [Full Text] [Related]

  • 10. Molecular genetics of gliomas.
    Appin CL, Brat DJ.
    Cancer J; 2014 Oct 01; 20(1):66-72. PubMed ID: 24445767
    [Abstract] [Full Text] [Related]

  • 11. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas.
    Cassoni P, Senetta R, Castellano I, Ortolan E, Bosco M, Magnani I, Ducati A.
    Am J Surg Pathol; 2007 May 01; 31(5):760-9. PubMed ID: 17460461
    [Abstract] [Full Text] [Related]

  • 12. Molecular subtypes of glioma identified by genome-wide methylation profiling.
    Kloosterhof NK, de Rooi JJ, Kros M, Eilers PH, Sillevis Smitt PA, van den Bent MJ, French PJ.
    Genes Chromosomes Cancer; 2013 Jul 01; 52(7):665-74. PubMed ID: 23629961
    [Abstract] [Full Text] [Related]

  • 13. Input of molecular analysis in medical management of primary brain tumor patients.
    Idbaih A, Duran-Peña A, Bonnet C, Ducray F.
    Rev Neurol (Paris); 2015 Jul 01; 171(6-7):457-65. PubMed ID: 26026669
    [Abstract] [Full Text] [Related]

  • 14. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.
    Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA, Zheludkova O, Milde T, Witt O, Kulozik AE, Reifenberger G, Jabado N, Perry A, Lichter P, von Deimling A, Pfister SM, Jones DT.
    Acta Neuropathol; 2015 May 01; 129(5):669-78. PubMed ID: 25752754
    [Abstract] [Full Text] [Related]

  • 15. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas.
    von Deimling A, Louis DN, von Ammon K, Petersen I, Wiestler OD, Seizinger BR.
    Cancer Res; 1992 Aug 01; 52(15):4277-9. PubMed ID: 1353411
    [Abstract] [Full Text] [Related]

  • 16. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
    Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H.
    Acta Neuropathol; 2002 Mar 01; 103(3):267-75. PubMed ID: 11907807
    [Abstract] [Full Text] [Related]

  • 17. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
    Gupta M, Djalilvand A, Brat DJ.
    Am J Clin Pathol; 2005 Nov 01; 124(5):755-68. PubMed ID: 16203285
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
    Shukla B, Agarwal S, Suri V, Pathak P, Sharma MC, Gupta D, Sharma BS, Suri A, Halder A, Sarkar C.
    Neurol India; 2009 Nov 01; 57(5):559-66. PubMed ID: 19934553
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.